Australia markets closed

Bionomics Limited (BNO.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.1500+0.0100 (+7.14%)
At close: 4:10PM AEDT
Full screen
Previous close0.1400
Bid0.1450 x 2640300
Ask0.1500 x 16362900
Day's range0.1400 - 0.1500
52-week range0.0924 - 0.4481
Avg. volume888,635
Market cap151.44M
Beta (5Y monthly)2.84
PE ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings date25 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.92
  • PR Newswire

    Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

    Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that as part of its broader pipeline expansion strategy and based on anti-anxiety signals in Generalised Anxiety Disorder (GAD) patients, it has decided to proceed with evaluating its lead clinical compound, BNC210, for acute treatment of Social Anxiety Disorder (SAD) with a planned commencement of a clinical trial by the end of this year.

  • Simply Wall St.

    The past three years for Bionomics (ASX:BNO) investors has not been profitable

    Bionomics Limited ( ASX:BNO ) shareholders should be happy to see the share price up 27% in the last month. But that is...

  • PR Newswire

    Bionomics Announces Plans to Conduct U.S. Initial Public Offering

    Bionomics Limited (ASX: BNO, OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United States and a concurrent listing of ADSs on Nasdaq. The number of ADSs and price of the proposed offering have not yet been determined. The proposed offering is expected to commence after the U.S. Securities and Exchange Commission completes its review proc